Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Teclistamab is an active T cell–redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma

21 Sept 2020

Abstract excerpt

B-cell maturation antigen (BCMA), a member of the tumor necrosis factor family of receptors, is predominantly expressed on the surface of terminally differentiated B cells. BCMA is highly expressed on plasmablasts and plasma cells from multiple myeloma (MM) patient samples. We developed a BCMAxCD3 bispecific antibody (teclistamab [JNJ-64007957]) to recruit and activate T cells to kill BCMA-expressing MM cells....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Monoclonal and Polyclonal Antibodies Research
Share to Multiple Myeloma Research and Treatments
Share to Peptidase Inhibition and Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32956453
DOI: 10.1182/bloodadvances.2020002393

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Teclistamab is an active T cell–redirecting bispecific antibody against B-cell maturation antigen for multiple myelomaPMID 32956453Read ↗

Teclistamab: Mechanism of action, clinical, and translational scienceSemantic proximity Read ↗

T-Cell Characteristics Impact Response and Resistance to T-Cell–Redirecting Bispecific Antibodies in Multiple MyelomaSemantic proximity Read ↗

Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple MyelomaSemantic proximity Read ↗

CAR T-cell therapy in multiple myeloma: mission accomplished?Semantic proximity Read ↗

T-cell engager bispecific antibodies enable T cells to eliminate Multiple Myeloma by targeting tumor CD38 in combination with PD-L1Semantic proximity Read ↗

A CS1-NKG2D Bispecific Antibody Collectively Activates Cytolytic Immune Cells against Multiple MyelomaSemantic proximity Read ↗

Design of a novel NanoCAR construct that compares well with a conventional ScFv-based CAR targeting BCMA on multiple myelomaSemantic proximity Read ↗

Both APRIL and antibody-fragment-based CAR T cells for myeloma induce BCMA downmodulation by trogocytosis and internalizationSemantic proximity Read ↗

Rapid BCMA downmodulation on myeloma cells upon CAR T cell contact is mediated by trogocytosis and BCMA internalizationSemantic proximity Read ↗

Engineering anti-BCMA CAR T cells for enhancing myeloma killing efficacy via apoptosis regulationSemantic proximity Read ↗

A longitudinal single-cell atlas to predict outcome and toxicity after BCMA-directed CAR T cell therapy in multiple myelomaSemantic proximity Read ↗

Bruton’s Tyrosine Kinase Targeting in Multiple MyelomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.